PDCD1 and melanoma: In conclusion, we determined that TGF-β2 inhibition by ngTASO enhances the T cell-mediated antitumor immunity of anti-PD-1 therapy by facilitating the intratumoral infiltration of CTLs, is partly associated with the downregulation of intrinsic β-catenin crosstalk, and consequently delays tumor growth in a melanoma-bearing HIS mouse model.